Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences, Inc. received a Schedule 13G reporting a new significant passive holder. Lind Global Fund III LP, together with Lind Global Partners III LLC and Jeff Easton, reports beneficial ownership of 141,265 shares of common stock, equal to 9.99% of the class as of 01/28/2026.
The position consists of 79,366 common shares plus 79,366 Series G warrants and 79,366 Series H warrants, all subject to a 9.99% beneficial ownership limitation that caps how many warrant shares can be converted at any time. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Enveric.
Enveric Biosciences, Inc. has a group of investors led by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting a passive stake in its common stock. As of the close of business on February 2, 2026, they may be deemed to beneficially own 71,246 shares, representing about 4.99% of the company’s common stock.
The holding includes 33,800 common shares and 37,446 shares issuable upon exercise of one warrant, while additional warrants are subject to 4.99% “blocker” provisions that limit further exercises. The investors certify the position was not acquired to change or influence control of Enveric Biosciences.
Enveric Biosciences entered into a financing that combines a registered direct stock sale with a concurrent private warrant placement. The company sold 328,802 common shares at $4.41 per share for gross proceeds of about $1.5 million and expects net proceeds of roughly $1.25 million after fees and expenses.
Investors in the private placement received Series G and Series H warrants to buy up to 328,802 shares each at an exercise price of $4.16 per share, exercisable immediately, with expirations tied to the effectiveness of a resale registration statement. H.C. Wainwright received cash fees, expense reimbursements and warrants to purchase 23,016 shares at $5.5125 per share for five years.
The company agreed to file a resale registration for the warrant shares within thirty days of closing and included a beneficial ownership cap of 4.99%, or 9.99% at the holder’s election, on warrant exercises. It also agreed not to issue additional equity or equity-linked securities for 15 days after closing, and plans to use the proceeds for product development, working capital and general corporate purposes.
Enveric Biosciences entered into a financing that combines a registered direct stock sale with a concurrent private warrant placement. The company sold 328,802 common shares at $4.41 per share for gross proceeds of about $1.5 million and expects net proceeds of roughly $1.25 million after fees and expenses.
Investors in the private placement received Series G and Series H warrants to buy up to 328,802 shares each at an exercise price of $4.16 per share, exercisable immediately, with expirations tied to the effectiveness of a resale registration statement. H.C. Wainwright received cash fees, expense reimbursements and warrants to purchase 23,016 shares at $5.5125 per share for five years.
The company agreed to file a resale registration for the warrant shares within thirty days of closing and included a beneficial ownership cap of 4.99%, or 9.99% at the holder’s election, on warrant exercises. It also agreed not to issue additional equity or equity-linked securities for 15 days after closing, and plans to use the proceeds for product development, working capital and general corporate purposes.
Enveric Biosciences is selling 328,802 shares of common stock in a registered direct offering at $4.41 per share, for gross proceeds of $1,450,016.82. Net proceeds are estimated at about $1.25 million after placement fees and expenses.
In a concurrent private placement, investors will also receive unregistered Series G and Series H warrants to purchase up to 328,802 shares each at an exercise price of $4.16 per share. Enveric plans to use the cash primarily for product development, working capital, and general corporate purposes. After the sale, common shares outstanding are expected to be 1,390,335, excluding shares issuable from warrants and equity awards.
Enveric Biosciences is selling 328,802 shares of common stock in a registered direct offering at $4.41 per share, for gross proceeds of $1,450,016.82. Net proceeds are estimated at about $1.25 million after placement fees and expenses.
In a concurrent private placement, investors will also receive unregistered Series G and Series H warrants to purchase up to 328,802 shares each at an exercise price of $4.16 per share. Enveric plans to use the cash primarily for product development, working capital, and general corporate purposes. After the sale, common shares outstanding are expected to be 1,390,335, excluding shares issuable from warrants and equity awards.
Enveric Biosciences, Inc. filed a current report to let investors know that it has prepared an updated Q1 2026 Investor Presentation. Management plans to post this presentation on the company’s website on or about January 9, 2026 and may use it in future meetings with investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and other interested parties.
The presentation is furnished as Exhibit 99.1 and is also accessible through Enveric’s investor events webpage, although website materials are not part of the report. The company specifies that the Investor Presentation is being “furnished” under Regulation FD rather than “filed,” which means it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.
Enveric Biosciences, Inc. is registering 131,110 additional shares of its common stock for issuance under its 2020 Long-Term Incentive Plan, as amended. This follows a board-approved equitable adjustment that increased the plan’s share pool to 164,148 shares after a 1-for-12 reverse stock split of the common stock that took effect on October 28, 2025. The shares registered are the same class as those previously registered on earlier Form S-8 filings and are intended to support stock-based compensation awards to employees, directors and other eligible participants.
Enveric Biosciences entered into warrant exercise inducement agreements with institutional holders of existing warrants for up to 426,390 shares, reducing the exercise price to $7.05 per share. In return, the company agreed to issue new Series E warrants for 426,390 shares and new Series F warrants for another 426,390 shares, plus placement agent warrants for 29,847 shares. Cash exercises of the existing warrants generated approximately $3.1 million in gross proceeds, which Enveric plans to use for product development, working capital and general corporate purposes.
The new warrants are immediately exercisable at $7.05 per share and will expire five years after the resale registration becomes effective for the Series E warrants and eighteen months after effectiveness for the Series F warrants. They include anti-dilution adjustments and caps that generally limit any holder to 4.99% ownership, or 9.99% with advance notice. Enveric also agreed to register the resale of the new warrant shares, temporarily restrict other equity issuances and registration filings, and avoid variable-rate transactions for one year after closing.
Enveric Biosciences reported the results of a Special Meeting of Stockholders held on December 11, 2025. A total of 2,502,133 shares of common stock were represented, equal to 40.23% of shares entitled to vote, which was enough for a quorum.
Stockholders approved an “Issuance Proposal” authorizing, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying certain warrants issued under prior inducement and engagement letters. They also approved a “Reverse Stock Split Proposal,” allowing the board, at its discretion, to implement a reverse split of issued and outstanding common stock at a ratio between 1-for-5 and 1-for-15.
In addition, stockholders approved an “Authorized Stock Increase Proposal” to amend the charter to increase authorized common shares from 100,000,000 to 5,000,000,000. Because all key proposals were approved, the adjournment proposal was moot, and no other matters were brought to a vote.
Enveric Biosciences Inc. has filed a prospectus covering the resale by existing investors of up to 418,313 shares of common stock issuable upon exercise of Series C, Series D and placement agent warrants. These shares are being registered for the selling stockholders, so Enveric will not receive proceeds from their resale, and will receive cash only if the warrants are exercised for cash rather than on a cashless basis. The warrants, most with an exercise price of $10.98 per share and the placement agent warrants at $13.7256, become exercisable only after stockholders approve the underlying share issuance, which Enveric is required to seek at a special meeting.
The warrant exercise inducement completed in September 2025 generated approximately $2.2 million in gross proceeds, supporting product development and working capital. Enveric recently effected a 1‑for‑12 reverse stock split and continues to post sizable net losses, reflecting its status as a clinical‑stage biotech developing non‑hallucinogenic neuroplastogenic drugs led by EB‑003 for difficult psychiatric and neurological disorders.
Enveric Biosciences (ENVB) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq notified the company on November 12, 2025, that the issue is resolved and the matter is now closed. This confirms ENVB’s continued listing on The Nasdaq Capital Market.